Table 1.
Clinical, radiologic, and histologic characteristics of all patients.
| Patient no. | Age at diagnosis (yrs)/gender | Interval between onset of symptoms and diagnosis (days) | Race/ethnicity | No. of gray matter areas affected | Histologic diagnosis/surgery | Therapy | Survival (yrs) |
|---|---|---|---|---|---|---|---|
| 1 | 1.0/F | 120 | Caucasian | 3 | AA/biopsy | Chemotherapy | 7.2 + |
| 2 | 2.4/M | 14 | Caucasian | 3 | Glioblastoma/STR | Chemotherapy | 0.5 |
| 3 | 2.4/M | 21 | Caucasian | 5 | AA/biopsy | RT + chemotherapy | 0.8 |
| 4 | 3.3/M | 1 | Mixed race | 4 | HGG with small cell features/STR | RT + chemotherapy | 1.0 |
| 5 | 4.3/F | 60 | Hispanic | 6 | AA/biopsy | RT + chemotherapy | 0.75 |
| 6 | 4.8/M | 5 | African‐American | 6 | GBM/STR | RT + chemotherapy | 1.0 |
| 7 | 5.4/M | 7 | Caucasian | 6 | AA/biopsy | RT + chemotherapy | 1.2 |
| 8 | 9.8/F | 35 | Caucasian | 7 | AA/biopsy | RT + chemotherapy | 1.5 |
| 9 | 10.7/M | 30 | Caucasian | 6 | AA/biopsy | RT + chemotherapy | 1.2 |
| 10 | 14.9/F | 42 | African‐American | 7 | Diffuse astrocytoma WHO grade II/biopsy | RT + chemotherapy | 1.75 |
| 11 | 15.7/F | 30 | Caucasian | 5 | AA/biopsy | RT + chemotherapy | 1.0 |
Abbreviations: No. = number; yrs = years; F = female; M = male; AA = anaplastic astrocytoma; GBM = glioblastoma; HGG = high‐grade glioma; WHO = World Health Organization; STR = subtotal resection; RT = radiation therapy.